Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 22, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - August 22, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/15/17 - A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability,...
By a News Reporter-Staff News Editor at China Weekly News Staff editors report on the newly launched clinical trial, NCT03237156, which has the following summary description: "The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male
8/15/17 - ABPI - Will biosimilars revolutionise the future of health
Release date- 15082017- The ABPI represents UK based pharma companies researching the newest and most innovative medicines. Our members make both originator biological medicines and make biosimilar medicines so, for want of a better word, we have a foot in both camps. We work to support the introduction of biosimilars but also work to ensure there
8/15/17 - Accuray Receives 510k Clearance for iDMS Data Management System Upgrade for the TomoTherapy System
By a News Reporter-Staff News Editor at Information Technology Newsweekly Accuray Incorporated announced it has received 510 clearance from the U.S. Food and Drug Administration for its iDMS? Data Management System, enabling its use with the Company's TomoTherapy platform. The iDMS System is a centralized database that shares and makes data
8/15/17 - Acella pharmaceuticals signs product development agreement with catalent to bring opioid-abuse deter
Release date- 14082017- ATLANTA- Acella Pharmaceuticals, LLC, a leading U.S. manufacturer of specialty pharmaceuticals across several therapeutic categories, today announced an exclusive, multi year, multi product development and licensing partnership with Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and.
8/15/17 - Aerie Pharmaceuticals Announces Appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons
Release date- 14082017- IRVINE, Calif.- Aerie Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of first in class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Me
8/15/17 - AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
Applied Genetics Technology Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies for the treatment of rare diseases, and the Foundation Fighting Blindness announced today a partnership agreement to support the organizations shared mission to advance gene therapy research to treat
8/15/17 - Allakos Announces Additions to Senior Leadership Team
Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced the appointments of two industry veterans to the leadership team. Robert Alexander, former Chief Executive Officer of ZS Pharma, has been...
8/15/17 - AMBROSUS Partners with TREK THERAPEUTICS to Develop a Blockchain-powered Method to Track Quality in Pharmaceutical Manufacturing
Zug, Switzerland and Boston, MA Ambrosus, the world's first trusted blockchain-based ecosystem for the supply chain, today announced a partnership with pharmaceutical pioneer Trek Therapeutics, PBC to apply integrated sensors coupled with blockchain-based technology to pharmaceutical drug manufacturing in Trek's clinical development program.
8/15/17 - Analytical Standards Market: Industry Players to Show High Growth Rate by 2024
Analytical Standards Market Forecasted Double-Digit Growth Rate Through 2024 Sarasota, FL 08/15/2017 Global Analytical Standards Market: OverviewThe specific property used to scale purity and quality of the drug and formulated medicine is called as an analytical standard. By assimilating methods, formulations, and drugs, they provide safety,
8/15/17 - AP Top Health News at 1:33 p.m. EDT
South Carolina sues drug manufacturer over opioid crisis Researchers to study chemical contamination of US waters New life for Medicaid after GOP's health care debacle Police try out new database for documenting opioid overdoses Texas doctor seeks to stop child abuse before it can happen 35 children die in north Indian hospital in 3 days Montana's
8/15/17 - Aphria Announces $11.5 Million Strategic Investment In Scientus Pharma
-Aphria Inc., is pleased to announce that it invested $11.5 million in HydRx Farms, Ltd. by way of a senior, secured convertible debenture. "We are excited to enhance our relationship with industry leader Scientus Pharma," said Vic Neufeld, Chief Executive Officer of Aphria. "We are excited to welcome Aphria as a strategic investor," said Trevor
8/15/17 - Aphria Invests $11.5 Million in Scientus Pharma
Aphria announced an investment of $11.5 million for Scientus Pharma through a secured convertible debenture. The Debenture has a two-year term, bears interest at the rate of 8%, paid semi-annually, is convertible into the common shares of Scientus Pharma at the rate of $2.75 a share and is secured by a first charge on all of the current and future
8/15/17 - Array BioPharma Appoints Curtis Oltmans as General Counsel
Release date- 14082017- BOULDER, Colo.- Array BioPharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced it has appointed Curtis Oltmans as General Counsel, effective immediately. Most recently, Mr. Oltmans served as Cor
8/15/17 - BioQ Pharma Secures up to $55 Million in Combined Debt and Equity Financing from Madryn Asset Management
BioQ Pharma Incorporated, a privately held specialty pharmaceutical company, today announced that it has secured new financing of up to $55 million from Madryn Asset Management, LP, an alternative asset management firm focused on investments in innovative healthcare companies. We believe BioQ s platform technology has the potential to radic
8/15/17 - CEL SCI CORP FILES (8-K) Disclosing Other Events
On August 14, 2017 the Company announced it has received a letter from the U.S. Food and Drug Administration stating that the clinical hold that had been imposed on the Company's Phase 3 cancer study with Multikine has been removed and that all clinical trial activities under this Investigational New Drug application may resume. On August 14, 2017
8/15/17 - CEOs have nothing to fear from Trump
At 8 Monday morning, Merck tweeted the news that its chief executive, Kenneth Frazier, was resigning from the American Manufacturing Council, a body made up of executives who are supposed to advise President Donald Trump on how to bring back the manufacturing sector. It was harsh, of course: "Now that Ken Frazier of Merck Pharma has resigned from P
8/15/17 - Cerecor Announces Divestiture of CERC 501 to Janssen Pharmaceuticals, Inc
Release date- 14082017- BALTIMORE, MD- Cerecor Inc., a biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that it has sold to Janssen Pharmaceuticals, Inc. all of its rights to CERC-501 for initial gross proceeds of $25 million, of which $3.75 million was depo
8/15/17 - Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer
Release date- 14082017- BALITIMORE, MD- Cerecor Inc., a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017.
8/15/17 - Clinical trial uses a genetically engineered virus to fight cancer
Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors. The Phase I immunotherapy trial is for those ages 18 and older with metastatic solid tumors that have not responded to standard treatments. The treatment injects an oncolytic virus ve
8/15/17 - Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection
Cocrystal Pharma, Inc., a clinical stage biopharmaceutical company focused on developing innovative antiviral therapeutics, today announced the successful completion and positive data from the Phase 1 a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus- infected individuals. CC-31244 is a...
8/15/17 - Conshy's Symphony Health drug-data firm sold for $520M []
Aug. 14 PRA Health Sciences Inc., a North Carolina- based clinical research organization that tests drugs, has agreed to pay $520 million for Symphony Health Solutions Corp., a Conshohocken- based medical data company assembled by Silicon Valley investors from mostly suburban Philadelphia- based firms that collected patients' drug prescriptions f
8/15/17 - Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI2 Trial in Gynecological Malignancies
Release date- 14082017- London, Ontario and Boston, MA- Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has completed the dose escalation portion of its Phase 1 study of COTI-2 in women with advanced gynecologic cancers who
8/15/17 - CV Sciences, Inc. Highlights Recent Research Showing Cannabidiol May Reduce Relapses in Smokeless Tobacco Addiction
CV Sciences, Inc. highlighted a recent study conducted at Federal University of Prana and Santa Catarina in Brazil which reports that preclinical and clinical studies suggested that cannabidiol may help prevent drug addiction relapse. CV Sciences is pioneering the development of a synthetic, pharmaceutical-grade CBD as an adjunct to nicotine...
8/15/17 - CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that the proof-of-concept study of seladelpar, a potent and selective PPAR agonist, for the treatment of primary biliary cholangitis was published by Lancet...
8/15/17 - Data on Colon Cancer Detailed by Researchers at Peking Union Medical College Hospital (Application of Circulating Tumor DNA as a Non-Invasive Tool...
Data on Colon Cancer Detailed by Researchers at Peking Union Medical College Hospital. By a News Reporter-Staff News Editor at Cancer Weekly Investigators publish new report on Oncology- Colon Cancer. Our news journalists obtained a quote from the research from Peking Union Medical College Hospital, "We used capture sequencing of 545 genes to ide
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement